The Ministry of Health, Labor and Welfare (MHLW) on November 27 granted the sakigake fast-track designation for Boehringer Ingelheim’s iclepertin and Nippon Shinyaku’s brogidirsen.Iclepertin was designated for the proposed indication of cognitive symptoms associated with schizophrenia. Meanwhile, brogidirsen nabbed the…
To read the full story
REGULATORY
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
- Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
- Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
- LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





